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Background: Chlorhexidine gluconate (CHG) is a broad-spectrum antiseptic agent 
that has become widely used for mouth care in intubated patients. Many studies have 
found it to be effective in the prevention of ventilator-associated pneumonia (VAP) when 
used after intubation; however, there is very limited research exploring the proper time to 
initiate CHG. Purpose: The purpose of this systematic review was to determine if the use 
of oral care with CHG prior to intubation impacts the incidence of VAP. Methods: The 
Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) was 
used to guide the selection process of articles and the Critical Appraisal Skills 
Programme (CASP) was used to critically appraise the randomized control trials (RCTs) 
selected for this systematic review. Four randomized RCTs met inclusion criteria. 
Results: Three of the four RCTs which met inclusion criteria, Houston et al. (2002), 
DeRiso et al. (1996), and Lin et al. (2015), showed an improvement in VAP rates with 
the use of preintubation CHG in cardiac surgery patients. Only one RCT, the Munro et al. 
(2015) study, showed no benefit; this was the only study that included non-cardiac 
surgery patients. Conclusion: Based on the results of this systematic review, it can only 
be recommended that cardiac surgery patients receive CHG prior to or after intubation; 
however, more research needs to be done to determine the most effective dosing, 
frequency, and CHG application procedure. In addition, further study exploring the safety 
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Does Oral Chlorhexidine Mouth Care Prior to Intubation Impact  
Ventilator-Associated Pneumonia?  
A Systematic Review 
Background/Statement of the Problem 
Hospital-acquired infections (HAIs) have a significant impact on mortality and 
health care costs. The five HAIs identified by the Centers for Disease Control and 
Prevention (CDC) include central line-associated bloodstream infections (CLABSI), 
catheter-associated urinary tract infection (CAUTI), surgical site infection (SSI), 
clostridium difficile-associated diarrhea (CDAD), and ventilator-associated pneumonia 
(VAP) (CDC, 2010). According to the National Nosocomial Infection Surveillance 
System VAP is the second most common nosocomial infection after urinary tract 
infections. Ventilator-associated pneumonia occurs in 9–27% of all intubated patients 
(American Thoracic Society; Infectious Diseases Society of America, 2005) leading to 
prolonged intubation and hospitalizations. A diagnosis of VAP can have a huge impact 
on mortality with an estimated cost upwards of $40,000 per patient and a mortality rate 
estimated between 27-76% (Klompas, Speck, Howell, et al., 2014).   
The Centers for Medicare and Medicaid Services listed VAP as one of the most 
reasonably preventable diseases. Sedwick et al. (2012) explain that since the centers view 
VAP as preventable, insurance companies may not reimburse hospitals for the diagnosis 
of VAP leading to a huge economic burden. With such a large mortality and financial 
burden, many hospitals utilize “VAP Bundles” which provide strategies to prevent the 
occurrence of VAP. Components of the VAP bundle may include: elevation of the head 
of the bed to 30º to 45º; prophylaxis for peptic ulcer disease; prophylaxis for deep-vein 
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thrombosis; daily interruption of sedation (sedation holiday); daily assessment of 
readiness for extubation; and daily oral care with chlorhexidine.  
Chlorhexidine gluconate (CHG) is a broad-spectrum antiseptic agent that has 
become widely used for mouth care in intubated patients. Many studies have found it to 
be effective in the prevention of VAP when used after intubation. There is very limited 
research exploring the proper time to initiate chlorhexidine. The purpose of this paper 
was to determine if the use of oral care with chlorhexidine prior to intubation impacts the 




A literature search was performed using CINHAL, Google Scholar, Cochrane, 
and Medscape combining the key terms: ventilator-associated pneumonia; chlorhexidine; 
and oral care. The additional term prior to intubation was also included later in the 
literature search. Literature was searched from 2005 to 2020. Searches were limited to the 
English language and articles that included adults 18 years and older.  
The Body’s Natural Defense Mechanisms for Prevention of Respiratory Infection 
A healthy person has multiple host defense mechanisms that hinder the 
development of pneumonia. The major defense mechanisms include airway barriers such 
as the epiglottis, cough reflexes, mucus, and mucociliary clearance (Safder et al., 2005). 
Mucosal ciliary move bacteria up and out of the bronchioles and a cough reflex assists 
this process. Additionally, the cellular and humoral immune systems help to eradicate 
potential pathogens on a cellular and extracellular level, respectively. In the mechanically 
ventilated patients, however, multiple factors compromise the body’s natural defenses 
such as critical illness, comorbidities, and malnutrition thereby impairing the immune 
system. Furthermore, endotracheal intubation blocks the cough reflex and mucociliary 
clearance, injures the tracheal epithelial surface, and provides a direct passage of bacteria 
into the lower respiratory tract (Safder et al., 2005). 
Pathophysiology of VAP  
Normally, the lower respiratory tract is sterile whereas pneumonia is an infection 
in the lungs that causes the air sacs, or alveoli, to fill up with fluid or pus. The major 
routes of VAP are from oropharyngeal colonization, from the stomach related to 
secondary colonization, or from endotracheal-tube (ETT) biofilms (Safder et al., 2005). A 
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biofilm is a collection of microbes that form an extracellular matrix or “slime” that traps 
bacteria or fungus and can lead to an infection (Bonez et al., 2013). The mechanical 
process of intubation alone facilitates microbial entry into the lungs by disrupting the 
body’s natural defense between the oropharynx and trachea allowing micro-aspiration. 
Critically ill patients may have a depressed level of consciousness further compounding 
the decreased gag reflex and pooling of secretions. Intubated patients are also at increased 
risk for the buildup of dental plaque and biofilms, which can harbor respiratory 
pathogens. This plaque accumulation may create an environment that allows for the 
adherence of organisms such as pseudomonas aeruginosa (Berry et al., 2011). The 
positive pressure from the ventilator then propels oral contaminants forward into the 
lungs.  
Diagnosis of VAP 
One of the significant challenges in diagnosing VAP is that there is no recognized 
diagnostic gold standard, leading to both under and over diagnosis. Many conditions in 
an intubated patient such as congestive heart failure or sepsis can mimic signs and 
symptoms of VAP as well as how they appear on imaging.  As a result, this may interfere 
with correct and timely diagnosis (Kollef, 2018).  
Ventilator-associated pneumonia is currently a clinical diagnosis made with a new 
or progressive lung infiltrate on imaging that coincides with clinical signs and symptoms 
of infection (i.e. leukocytosis, purulent secretions, and fever) as well as a positive 
pathogen from a respiratory sample (Kollef, 2018). Pneumonia is considered a VAP 
when it occurs more than 48-72 hours post endotracheal intubation. With the presence of 
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radiologic infiltrates and two clinical criteria, the sensitivity of diagnosing VAP is 69% 
and the specificity is 75% (Amanullah, 2015).  
Healthcare providers rely upon radiographic, clinical, and laboratory indicators to 
diagnose VAP and initiate empiric antibiotics. Some of these have been combined into 
clinical diagnostic models, the most popular of which is the Clinical Pulmonary Infection 
Score (CPIS). This tool was developed to facilitate the diagnosis of VAP based on points 
assigned for each of the following signs and symptoms of pneumonia: tracheal secretions, 
temperature, white blood cell (WBC) count, oxygenation, chest radiograph, and tracheal 
aspirate culture. A score of > 6 indicates a VAP is more likely. 
A systematic review and meta-analysis by Fernando et al., 2020 sought to 
characterize and compare the accuracy of physical examination, chest radiography, 
endotracheal aspirate (ETA), bronchoscopic sampling cultures, and CPIS > 6 to diagnose 
VAP. Researchers included 25 studies totaling 1639 patients. Inclusion criteria included: 
English-language articles through 2019, retrospective and prospective observational 
studies, RCTs, adult intensive care unit (ICU) patients ≥ 16 years, and invasive 
mechanical ventilation ≥ 48 hours. Additionally, the studies must have evaluated one or 
more of the following characteristics: fever (defined as body temperature ≥ 38 degrees 
Celsius), purulent secretions, leukocytosis (any threshold), chest radiography, gram stain 
and/or culture from the lungs, or CPIS for diagnosis of VAP. Histopathological analysis 
from lung biopsy and bronchoalveolar lavage (BAL) were the primary and secondary 
reference standards, respectively. The two researchers independently extracted data and 
assessed study quality. 
6 
 
Fernando et al. (2020) found that none of the clinical diagnostic methods used to 
diagnose VAP were very accurate. The pooled sensitivity and specificity of physical 
examination findings for VAP were poor: fever (66.4% [95% CI: 40.7–85.0], 53.9% 
[95% CI 34.5–72.2]) and purulent secretions (77.0% [95% CI 64.7–85.9], 39.0% [95% 
CI 25.8–54.0]). An infiltrate on chest radiography had a sensitivity of 88.9% (95% CI 
73.9–95.8) and specificity of 26.1% (95% CI 15.1–41.4). ETA had a sensitivity of 75.7% 
(95% CI 51.5–90.1) and specificity of 67.9% (95% CI 40.5–86.8). Protected specimen 
brush bronchoscopy (PSB) had a sensitivity of 61.4% [95% CI 43.7–76.5] and specificity 
of 76.5% [95% CI 64.2–85.6]; while BAL had a sensitivity of 71.1% [95% CI 49.9–85.9] 
and specificity of 79.6% [95% CI 66.2–85.9]. CPIS > 6 had a sensitivity of 73.8% (95% 
CI 50.6–88.5) and specificity of 66.4% (95% CI 43.9–83.3). The findings were consistent 
when using either reference standard.  
The presence of infiltrate on chest radiography had the highest sensitivity of 
88.9% but had poor specificity. The CPIS was deemed inaccurate by researchers 
regardless of the reference standard used. This meta-analysis suggests that the methods 
clinicians routinely use to diagnose VAP and initiate antibiotics in the ICU are neither 
sensitive nor specific.  
The study has some limitations; it does not include the sensitivity and specificity 
of histopathology from lung biopsy and this was the reference standard utilized 
suggesting it is most accurate. They did state it was impractical for routine diagnosis, and 
that results may be influenced by the area of the lung that is biopsied. The study used 
published data so not all details of subjects included may have been known as well as if 
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patients were on antibiotics prior to bronchoscopic sampling, both of which may 
confound the results.  
Consequences of VAP 
Ventilator-associated pneumonia is correlated with increases in mortality, length 
of stay, and exponential increases in health care costs. A patient with VAP remains in the 
ICU 4 to 19 days longer than patients who were intubated and did not acquire a VAP. 
This longer stay is associated with higher costs. The cost of care for a patient with VAP is 
approximately $40,000 to $57,000 higher than the cost for a patient on mechanical 
ventilation without  VAP (Sedwick et al., 2012). The mortality rate for VAP ranges from 
27-76% (Amanullah, 2015).  
VAP Bundles 
The 100,000 Lives Campaign was a nationwide initiative launched by the Institute 
for Healthcare Improvement (IHI) in 2006 with a goal to reduce morbidity and mortality 
in health care in the United States. The campaign focused on six key areas for 
improvement including: initiating rapid response teams; acute myocardial infarction 
interventions; preventing adverse drug reactions; preventing central line infections; 
preventing surgical site infections; and preventing VAP (IHI, n.d.).    
The IHI recommends VAP bundles, which are evidenced-based interventions, to 
improve patient outcomes. The VAP bundle originally included: elevation of the head of 
bed between 30 and 45 degrees, daily sedation interruptions, daily assessment of 
readiness to extubate, stress ulcer prophylaxis, and deep vein thrombosis prophylaxis. In 
the spring of 2010, after new clinical trials were examined, oral care with chlorhexidine 
0.12% was added to the bundle. 
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Recent evidence has challenged the VAP bundle and added further up to date 
recommendations on interventions. “Strategies to Prevent Ventilator-Associated 
Pneumonia in Acute Care Hospitals: 2014 Update” was published to update the 2008 
guidelines to include the new recommendations of the use of subglottic secretion 
drainage ports for patients likely to require intubation >48 hours and only changing the 
ventilator circuit as needed rather than on a fixed schedule. The subglottic suction drains 
potential pathogens that pool above the ETT. The humidified gas in the ventilator circuit 
is at increased risk for contamination with frequent manipulation and would have direct 
entry through the ETT into the lungs. The new guidelines also do not recommend the use 
of stress ulcer prophylaxis as it did not have an impact on VAP rates (Klompas, Branson, 
Eichenwald, et al., 2014). The Intensive Care Society (ICS) and the National Institute for 
Health and Care Excellence (NICE) recently withdrew its recommendation for the use of 
oral chlorhexidine in non-cardiac surgery patients in 2016 after a new meta-analysis 
suggested its association with an increase in mortality (Hellyer et al., 2016). The exact 
mechanism resulting in higher mortality rates remains unclear, but it may be that some 
patients aspirate chlorhexidine and develop acute respiratory distress syndrome (ARDS) 
(Price et al., 2014).  
Although many medical experts believe that the campaign has been a success, the 
IHI has not been able to accurately calculate and quantify the data (IHI, n.d.). A 
systematic review by Lawrence and Fulbrook (2011) examined the impact of VAP 
bundles on the incidence of VAP. Inclusion criteria included English language 
experimental studies between 2004-2009, clinical outcomes measured, and studies that 
included head of the bed minimum of 30 degrees, daily sedation holiday, gastric ulcer 
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prevention, and DVT prophylaxis. Ten studies were included in the review. Three of the 
studies had chlorhexidine mouth care as a bundle component. The studies included were 
observational with no control group because the researchers deemed it unethical to not 
implement the IHI’s recommendation for the bundle. Therefore, the researchers could not 
definitively conclude a causal relationship between the bundle implementation and 
incidence of VAP; however, there was a positive association.   
Chlorhexidine and Oral Care 
Oral CHG is a prescribed antiseptic that reduces microbial colonization in the oral 
cavity. It covers a broad spectrum of microorganisms including gram-positive bacteria, 
gram-negative bacteria, and yeast. A 0.12% concentration is currently the only oral 
formulation approved by the Food and Drug Administration (FDA) for use in the United 
States (Grap et al., 2017). This germicidal rinse is typically used to treat gum disease such 
as gingivitis and periodontitis in adults. It has been adopted into oral care protocols up to 
twice daily for mechanically ventilated patients to decrease the pathogen load in oral 
plaque and the risk of VAP.  
The technique of applying CHG during oral care is done by rinsing the mouth 
with a CHG solution using a sponge or toothbrush followed by oral suction; generally, a 
suction catheter kit that has a toothbrush or sponge is used.  Some manufacturers sell 
commercially packaged “24-hour systems” which include all-inclusive kits with 
individually packaged products to use every two to four hours for mouth care. The kits 
may include mouth moisturizer for every two to four hours and chlorhexidine solution for 
twice daily oral care (Q•CareOral Cleansing & Suctioning Systems, 2018). Many 
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hospitals are utilizing these kits; however, there are no universal protocols for continuity 
between hospitals on exact mouth care procedures and products used.  
 A prospective, randomized, double-blind, placebo-controlled clinical trial by 
Ćabov et al. (2010) included a total of 60 intubated patients in a surgical ICU in Croatia 
assessed whether oral CHG mouth care impacted dental plaque, colonization of the oral 
cavity, and nosocomial infections. The control group received standard oral care, which 
consisted of rinsing the mouth with bicarbonate isotonic solution and gentle 
oropharyngeal sterile suctioning followed by the application of a placebo gel. The 
experimental group received the same standard care with the addition of a 0.2% 
chlorhexidine gel rubbed on the teeth by a gloved finger of a nurse three times daily. 
Dental status, plaque samples, nasal and tracheal aspirates, and urine samples were 
obtained 24 hours after admission and then every three days until discharge. Dental status 
was assessed using the caries-absent-occluded (CAO) dental index which is calculated as 
the sum of decayed, missing, and filled teeth and ranges from 0 (normal dental status) to 
28 (all teeth absent or decayed). The study found that 63% of patients had preexisting 
colonized dental plaque and oral mucosa with multiple aerobic organisms on admission. 
Moreover, they found a positive correlation between colonized dental plaque and the 
development of numerous nosocomial infections such as bacteremia, UTI, or VAP. The 
rate of these nosocomial infections was four times lower in the group receiving the 
chlorhexidine oral care. The most frequently acquired nosocomial infection was 
pneumonia, with a statistically higher rate of occurrence in the placebo group. More 
specifically, the number of cases of pneumonia was significantly higher in the placebo 
group (6/30) than the chlorhexidine group (1/30) (p=0.039) (Ćabov et al., 2010). The 
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number of patients being admitted colonized with pathogens that cause VAP paired with 
the positive correlation of chlorhexidine reducing infection rates, supports the theory that 
chlorhexidine oral care prior to intubation may impact and potentially reduce VAP rates.  
 The study had some notable limitations. The sample size was small, having only  
60 patients, which decreases the power of the study’s results. The study also did not 
compare the differences in infection rates between the patients that came in with 
colonization versus those that did not. Patients were first randomized into a group by 
computer generation then swabbed for colonization on admission after being assigned a 
group. However, the researchers stated there was no statistical differences in bacterial 
colonization of dental plaque (P = 0.21) or buccal mucosa (P = 0.42) between the groups 
on day 0.  
CHG and the Prevention of VAP in Mechanically Ventilated Patients  
Saliva acts as a lubricant to the oral cavity and provides antibacterial and 
buffering properties in healthy patients. Mechanically ventilated patients may lack saliva 
related to side effects from the multiple medications they are receiving and prolonged 
mouth opening related to the ETT (Hua et al., 2016). Regularly scheduled oral care is 
intended to mimic the function of the saliva by moistening the mouth as well as removing 
debris and plaque (Hua et al., 2016). Using an antiseptic such as CHG, may further 
reduce the bacterial burden or delay a subsequent increase in bacterial burden (Hua et al., 
2016). Decreasing the bacterial burden from the oral cavity would reduce the opportunity 




A systematic review by Hua et al. (2016) analyzed 38 randomized controls trials 
comparing four main groups of interventions (CHG mouth rinse vs. placebo, 
toothbrushing vs. no toothbrushing, powered toothbrush vs. oral care with manual 
toothbrush, oral care with other solutions) in the oral hygiene care of critically ill patients 
receiving mechanical ventilation for at least 48 hours in intensive care units. The 18 
RCTs that compared CHG versus placebo used concentrations 0.12%, 0.2%, 1%, and 2%. 
The study found the use of chlorhexidine reduced the risk of VAP compared to placebo 
from 24% to 18% (P = 0.004). There was no evidence that use of CHG was associated 
with a difference in mortality, duration of mechanical ventilation or duration of ICU stay.  
There were some limitations in this systematic review including the potential bias 
in the variation and subjective nature of criteria used for VAP diagnosis per each study. 
This makes it difficult to compare VAP results when different diagnostic tools were used 
to define VAP. Also, the specific details of what was involved in the oral hygiene care 
intervention were poorly described in some of the studies.  
Klompas, Speck, Howell, et al. (2014) conducted a systematic review and meta-
analysis of 16 RCTs examining the use of CHG versus placebo on the incidence of VAP. 
Researchers sought to reappraise the evidence after noting bias in previous systematic 
reviews. Previous reviews included studies with a majority of cardiac surgery patients 
that were primarily extubated within 24 hours and that little distinction was made 
between open-label versus double-blind investigations leading to bias in favor of CHG 
use. Due to the lack of gold standard for the diagnosis of VAP the researchers chose to 
compare duration of mechanical ventilation, length of stay, and mortality as more 
objective patient-centered outcomes. Inclusion criterion was RCTs evaluating daily oral 
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care with CHG (any preparation) versus a placebo in adult patients receiving mechanical 
ventilation. Data bases were searched without date restrictions and previously published 
meta-analyses and the reference lists of all suggestive articles were reviewed for 
inclusion. Cardiac surgery studies accounted for 51% of patients and non–cardiac surgery 
investigations included 49% of patients in this review.  
The results indicated there were fewer lower respiratory tract infections in cardiac 
surgery patients receiving chlorhexidine (relative risk (RR), 0.56; 95% confidence 
interval (CI), 0.41-0.77) but no significant difference in VAP in noncardiac surgery 
patients (RR, 0.88; 95% CI, 0.66-1.16). There was no significant difference in mean 
duration of mechanical ventilation or intensive care length of stay in either groups. There 
was a nonsignificant result of increased mortality with chlorhexidine use among non– 
cardiac surgery studies. Limitations included the pulmonary outcomes in the cardiac 
surgery studies were specified as “nosocomial pneumonia,” “upper respiratory tract 
infections,” “lower respiratory tract infections,” or “total respiratory tract infections” 
(Klompas, Speck, Howell, et al. 2014), but in all non–cardiac surgery studies the 
outcomes were defined as VAP. No further definitions were given as to what criteria 
were used to diagnose these.  
Deschepper et. al. (2018) conducted a retrospective, observational cohort study 
including 82,274 patients hospitalized in various settings in Belgium with the objective of 
assessing the effect of CHG oral care on mortality. Oral care with 15 mL 0.05% or 0.12% 
CHG was given twice daily on general wards and three times daily to ICU patients.  A 
proxy measure for CHG exposure was defined as low ≤ 300 mg or high > 300 mg, 
respectively. Independent patients were given instructions to swish and spit and 
14 
 
dependent patients had oral swabbing provided by nurses. This two-year study included 
patients 16 years or more with adjustment for risk of mortality and severity of illness 
based on the All Patient Refined-Diagnosis Related Groups (APR-DRG). Patients 
without APR-DRG risk of mortality were excluded as well as childbirth related 
admissions.  
A total of 14% of patients hospitalized and discharged between 1 January 2012 
and 31 December 2014 that met inclusion criteria received CHG oral care during their 
hospitalization, either in a solution of 0.05% (n = 1175) or 0.12% (n = 9963). The study 
found no association between CHG oral care and increased mortality in postoperative 
cardiothoracic and vascular surgery patients or patients receiving mechanical ventilation. 
In cardiothoracic and vascular surgery patients the relationship between CHG oral care 
and mortality did not reach statistical significance (CHG exposure ≤ 300 mg odds ratio 
(OR) 0.96; 95% CI 0.60–1.55; P = 0.874, CHG exposure > 300 mg OR 1.43; 95% CI 
0.88–2.32; P = 0.146). CHG oral care was associated with increased risk of death in 
patients who were not admitted to the ICU and those that did not receive mechanical 
ventilation. Overall, the patient’s with better prognosis on risk assessment for mortality 
was associated with a greater chance for adverse effects related to CHG oral care.  
The study has several limitations including its observational design which is 
prone to bias. Also, it is unclear why there were two different doses (0.05% and 0.12%) 
of CHG, why one was indicated over the other, and why only 14% of patients included in 
the study received CHG oral care during their hospitalization. This is a small percentage 
of their sample size and is the purpose of the study. Perhaps more strict inclusion criteria 
were required to yield a higher percentage. The lack of a tangible pathogenic mechanism 
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leading to increased risk of mortality leaves the data difficult to interpret. The study 
proposes micro-aspiration of CHG leading to ARDS or anaphylactic reactions as 
potential links to increased mortality but states further research is indicated with these 
outcome criteria.  
Varying evidence supports the use of chlorhexidine in select populations and it is 
being utilized in ICUs throughout the United States, but little research has been done to 
study when chlorhexidine should be initiated. Given that there is some evidence that 
CHG use decreases VAP rates and that intubation is a risk for infection, it could be 
hypothesized that the use of oral chlorhexidine prior to intubation would decrease VAP 
rates. 
Chlorhexidine Prior to Intubation and VAP Prevention  
As previously discussed, the process of intubation is a risk factor for VAP as the 
ETT passes through the microbe rich oropharynx and down into the lungs. In most other 
invasive clinical procedures where a tube is inserted, decontamination procedures are 
done at the insertion site to reduce the risk of colonization or infection. For example, 
prior to a urinary catheter insertion the meatus is scrubbed with an antiseptic. 
Endotracheal intubation usually proceeds without any preparation of the mouth other than 
the removal of dentures and potentially suctioning of oral secretions. The use of oral 
chlorhexidine prior to intubation could potentially eliminate the risk of introducing 
microbes from the oral cavity into the lungs during the intubation procedure (Munro et 
al., 2015). 
Nicolosi et al. (2014) conducted a quasi-experimental study to test this 
hypothesis. The study took place in a large hospital in Argentina and included patients 
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undergoing cardiothoracic surgery. The control and experimental group each included 
123 patients. The control group received the hospital’s standard preoperative protocol of 
mupirocin antibiotic nasally for three days prior to surgery, administration of a third-
generation cephalosporin 30 minutes before and after surgery, and continuation of the 
patient’s normal oral routine prior to admission. The experimental group received the 
same treatment with the addition of 0.12% CHG every 12 hours for three days 
preoperatively with education on proper tooth brushing techniques by a dentist. The 
measurable outcome was the development of VAP. The group that received oral 
decontamination preoperatively with chlorhexidine had a VAP rate of 2.7% while the 
control group had a rate of 8.7% demonstrating the risk of developing VAP after surgery 
was more than 3 times greater in patients who did not receive oral decontamination with 
chlorhexidine. Study limitations include its small sample size and its quasi-experimental 
design. 
A similar prospective intervention study by Bergan et al. (2013) tested the same 
hypothesis including 226 patients undergoing cardiothoracic surgery at a federal public 
hospital in Brazil. Patients received education from a dentist on proper tooth brushing 
techniques and were instructed to rinse their mouth and gargle with CHG 0.12 % twice a 
day for 2 minutes and just prior to the operating room. Postoperatively, the nurses 
performed the toothbrushing and CHG oral care. The measurable outcome was diagnosis 
of VAP. All patients received two grams of cefazolin 30 minutes before cardiac surgery 
as standard preoperative prophylaxis. Prior to the implementation of the CHG, the VAP 
rate was 32 per 1,000 (3.2) ventilator-days; the rate declined to 10 per 1,000 (1) 
ventilator-days within one year of the start of the new protocol. The hospital had a 69% 
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reduction in the incidence of VAP by 12 months. This is significant since the study also 
found the presence of pneumonia increased the chances of death by 11 times, P < 0.0001. 
Mortality in patients with pneumonia was 6/19 (33.3 %) versus 9/208 (4.32 %) in those 
without pneumonia. Limitations include small sample size and being a single center study 
in the setting of a developing country. The study does speculate that cardiac surgery 
patients at their institution have lower postoperative pneumonia rates related to their 
regular referrals for dental care preoperatively to prevent endocarditis.  
There are limited randomized control trials investigating the use of oral 
chlorhexidine prior to intubation and the impact on the incidence of VAP. Four published 






Louis Pasteur proposed the germ theory in 1858 theorizing that specific organisms 
are capable of causing infectious diseases. This simple cause and effect theory has been 
critical to the development of modern medical care and its impact has helped to 
drastically decrease the number of deaths from infection (Mcewen & Wills, 2011). 
Pasteur’s theory is predominantly utilized in disease prevention and epidemiological 
studies. The theory seeks to identify, understand, and manage infectious diseases leading 
to the development of ways to prevent and treat disease. 
This systematic review utilizes the principles of Pasteur’s germ theory. During the 
literature review, the problem of VAP was identified and explored. Causative 
mechanisms were further investigated with intubation and biofilms identified as leading 
factors. Methods to prevent VAP were explored specifically focusing on chlorhexidine 





A systematic review was conducted to determine if the use of oral care with 
chlorhexidine prior to intubation impacts the incidence of ventilator-associated 
pneumonia. The Preferred Reporting Items for Systematic reviews and Meta-Analyses 
(PRISMA) was used to guide the selection process of articles and the Critical Appraisal 
Skills Programme (CASP) was used to critically appraise the randomized control trials 
selected for this systematic review. The ethical considerations for this systematic review 
are that PRISMA, as well as the inclusion and exclusion criteria, were strictly followed.  
Using the PRISMA checklist (Appendix A) and the flow diagram (Appendix B), a 
comprehensive literature search for RCTs was performed using the databases CINHAL, 
Google Scholar, and Medscape and combining the key terms: ventilator-associated 
pneumonia; chlorhexidine; oral care; and prior to intubation. The inclusion criteria 
included randomized control trials, age greater than 18 years, and receiving oral 
chlorhexidine prior to being intubated. The study had to compare the use of chlorhexidine 
mouth care prior to intubation versus not using chlorhexidine prior to intubation and the 
incidence of VAP had to be the measurable outcome. Only articles published in English 
were reviewed. Exclusion criteria were randomized control trials that did not use 
chlorhexidine prior to intubation, participants less than 18 years old, non-English 
language articles, studies that were not randomized control trials, and studies that did not 
have VAP as the measurable outcome. Literature was searched initially from 2006 to 
2020 and then with no date restriction using the above-mentioned inclusion and exclusion 
criteria related to the limited number of RCTs available on this topic.  
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PRISMA consists of a 27-item checklist (Appendix A) and a four-phase flow 
diagram (Appendix B) that dictates the steps of the evaluation of each study and in turn 
allows for presentation of the information in a precise and consistent manner. The 
checklist includes the major sections of a systematic review and what is to be included in 
each section. These sections include the major categories of title, abstract, introduction, 
methods, results, and funding (Moher et al., 2009). There are also several subcategories 
within each section. The PRISMA checklist was utilized to ensure data extracted from 
each of the included randomized control trials was complete and consistent. 
The four-phase flow diagram (Appendix B), including identification, screening, 
eligibility, and inclusion, was used to select the articles appraised for the systematic 
review (Moher et al., 2009). Identification involves identifying records through databases 
and other sources. Screening involves refining the search to only pertinent studies related 
to the specific research question at hand and eliminating any duplicates that occur.  The 
eligibility phase uses inclusion and exclusion criteria to omit any studies that do not meet 
criteria and includes an explanation of why. Lastly, the inclusion phase is the final 
number of studies that will be used in the systematic review. Using this four-phase 
process, studies were identified, screened for duplicates, and assessed for eligibility, 
which resulted in a select number of studies to be used in this systematic review. 
Once the randomized control trials were selected, each article was analyzed and 
pertinent data was presented in an organized table (Appendix C1-4) allowing for 
comparison of the studies’ purposes, designs, sites and samples, methods, results, and 
limitations. Each randomized control trial was then critically appraised using the CASP 
checklist for RCTs to determine the studies’ scientific integrity (Appendix D1-4). 
21 
 
The CASP is part of the Oxford Centre for Triple Value Healthcare and strives to 
systematically assess the trustworthiness, relevance, and results of published papers. The 
CASP checklist for randomized control trials is an 11-question standardized checklist to 
methodically determine the quality, validity, and integrity of a study (CASP, 2018).  
Lastly, a cross study analysis (Appendix E1-4) was performed to compare the 
placebo used in each study, the CHG dose selected, and the effect on incidence of VAP.  





















The search terms yielded 236 results; 62 duplicates were eliminated leaving 174 
remaining for review. The abstracts were then reviewed to determine if they met 
inclusion and exclusion criteria; 16 articles remained. The full texts of the remaining 
articles were read and assessed for the inclusion/exclusion criteria, leaving a total of 4 
articles that were used in this systematic review. Pertinent data from each article was 
organized into data a table (Appendix C). Next, each study was summarized as follows 
and the studies were critically appraised using the CASP checklist (Appendix D). 
Study Characteristics 
A randomized control trial by Munro et al. (2015) (Appendix C1) evaluated the 
benefit of adding a preintubation CHG dose to the hospital’s standard postintubation 
CHG to reduce the risk of VAP. Prior to intubation, study personnel swabbed the oral 
cavity with 5 mL of a 0.12% CHG. Postintubation, the same dose and concentration of 
CHG was administered by the responsible nurse on a twice daily schedule until 
extubation. A secondary aim was to test the effect of a preintubation oral application of 
CHG on early endotracheal tube (ETT) colonization. The RCT included 314 subjects 
from two large Southern urban teaching hospitals in the United States. Immediately prior 
to intubation, subjects were recruited from multiple clinical areas, including critical care 
units, emergency departments, preoperative areas, procedural areas, and medical surgical 
units during rapid response or code calls. The CHG group was 58% male with a mean 
age of 58.1 years and a mean Acute Physiology and Chronic Health Evaluation 
(APACHE) score of 69.1. The control group consisted of 62% males with a mean age of 
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58.2 years and a mean APACHE score of 65.1. Patients with a clinical diagnosis of 
pneumonia at the time of intubation were excluded.  
Subjects were randomly assigned to the intervention group that received oral 
application of 5 mL 0.12% CHG by oral swab or the control group that received no 
preintubation intervention. All subjects received CHG twice a day after intubation as 
standard of care. The Clinical Pulmonary Infection Score (CPIS) was used to evaluate the 
risk of VAP with a VAP threshold score of > 6. Any score > 6 signified an increased risk 
for VAP.  Researchers chose the CPIS to evaluate the risk of early-onset VAP because it 
permitted serial prospective evaluation of VAP risk without substantially increasing risks 
to human subjects. A swab was taken of the distal ETT after extubation to assess the 
secondary aim of ET colonization.  
The results of this study (Appendix E1) demonstrated no statistically significant 
improvement in CPIS scores from the CHG group over the control group. The mean 
CPIS scores from both groups remained below the VAP threshold of 6 signifying a VAP 
was not likely. Regarding the study’s secondary aim of ETT colonization occurrence, the 
majority of ETTs in both study groups were not colonized at the time of extubation 
(81.4% in the CHG group and 82.5% in the control group). There was no statistically 
significant difference in ETT colonization between the groups (P = 0.8656). 
Critical analysis of the Munro et al. (2015) study using the CASP checklist 
(Appendix D-1) revealed both groups were statistically similar. Although the sample size 
was small, a priori power analysis was used to determine the sample size required to 
detect a difference in CPIS of 1 between the two groups. The clinical providers were 
blinded to study group assignment, as well as the clinical laboratory personnel who 
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performed microbial analyses and the coinvestigator who evaluated the chest x-rays. This 
study had several limitations. Nine subjects in the CHG group did not receive the 
intervention and the study does not explain why.  Furthermore, there were four subjects 
listed as “other” that did not remain in the intervention group and eight that did not 
remain in the control group without rationale as to why. The study reported most subjects 
were extubated prior to the full 5-day intervention period leading to unavoidable attrition 
over the course of the study. There was no mention of a standard mouth care swabbing 
technique or training to ensure continuity and it was being performed by hospital nurses 
not study personnel. The possibility of data entry error exists due to the possibility that 
CHG administration was recorded but not actually performed.  The CPIS score used as a 
diagnostic tool for VAP in the study only had a sensitivity of 73.8% and specificity of 
66.4% (Fernando et al., 2020). Lastly, it is not made clear how randomization was 
achieved or what additional inclusion criteria was used besides prior to intubation without 
an existing diagnosis of pneumonia. 
Houston et al. (2002) tested the effectiveness of 0.12% CHG oral rinse compared 
to the standard control of phenolic mixture (Listerine) in decreasing microbial 
colonization of the respiratory tract and hospital-acquired pneumonia in patients 
undergoing open heart surgery. A total of 561 patients undergoing aortocoronary bypass 
or valve surgery requiring cardiopulmonary bypass were randomized to an experimental 
(n = 270) or a control (n = 291) group. The CHG group was 73% male, and the Listerine 
group was 79% male. Patients were excluded from the study if they died during surgery, 
were pregnant, or had a documented or patient reported preoperative respiratory 
infection. Patients were randomized by medical record numbers. Preoperatively, both 
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groups received 15 mL of their respective oral rinse to swish and spit and postoperatively 
received the same by mouth swab twice daily until extubation, tracheostomy, death, or 
diagnosis of pneumonia. Both groups received preoperative and perioperative 
prophylactic antibiotics as part of the routine cardiac surgery protocol. Sputum samples 
were collected every 48 hours until extubation. VAP was diagnosed using criteria 
established by the Centers for Disease Control and Prevention.  
Results of this study (Appendix E-2) revealed that VAP rates did not differ 
significantly (4/270 vs. 9/291; P=0.21) in the CHG group compared to the Listerine 
group. The study also found that only patients intubated for more than 24 hours 
developed pneumonia (0/486 vs. 13/75; P = 0.01). The pneumonia rate was reduced by 
58% (4/19 vs. 9/18; P = 0.06) overall in patients treated with CHG who were intubated 
for more than 24 hours and had sputum cultures that showed positive microbial growth. 
In patients at highest risk for pneumonia (intubated > 24 hours, with sputum cultures 
showing the most growth), the rate was 71% lower in the CHG group than in the 
Listerine group (2/10 vs. 7/10; P =.02).  
Critical analysis of the Houston et al. (2015) study using the CASP checklist 
(Appendix D-2) showed the two groups did not differ significantly in characteristics. 
None of the patients extubated within hours of surgery developed pneumonia. Most 
patients included in this study were extubated within hours of surgery, therefore, a 
limitation may be the relatively small sample size. However, the sample size of 600 was 
projected based on the hospital’s historical rate of VAP and was deemed sufficient to 
detect a 0.20 effect size with 99% power. Perhaps the biggest limitation of the study is 
that the researchers did not disclose whether the participants or providers were blinded. 
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Age ranges of participants were not included. The study does not state how many doses 
of oral rinse patients received in total preoperatively. There also could be error in self-
reporting of the preoperative doses that patients did independently at home. Some doses 
may have been skipped and not reported. The study refers to attrition resulting from death 
and tracheostomy. However, it is not disclosed how many patients were properly 
accounted for at the conclusion of the study.  
DeRiso et al. (1996) examined whether twice daily preoperative use of 0.12% 
CHG oral rinse reduced hospital-acquired infection rates in patients undergoing open 
heart surgery in a prospective, randomized, double-blind, and placebo-controlled study. 
Of the 353 patients who were included, 173 patients were randomized to the CHG group 
and 180 to the placebo group. The CHG group was 69% male with the mean age of 64.1 
years and the control group was 68% male with the mean age of 63.5 years. The chemical 
make-up of the base solution of both the intervention and placebo oral rinses was similar; 
the placebo had no antimicrobial properties. Each group received their respective oral 
rinse twice daily preoperatively with an unspecified number of doses and postoperatively 
twice daily until discharge from the ICU or death. Prophylactic antibiotics and 
intravenous ranitidine were given as standard postoperative care. Exclusion criteria were 
intraoperative death, preoperative infection or intubation, pregnancy, heart and lung 
transplant recipients, and known hypersensitivity to CHG. The patients who failed early 
extubation received tracheal aspirate culture at 48 hours and then every two days until 
discharge from the ICU or death. This study also used the CDC’s diagnostic infection 
criteria for VAP. Outcomes measured were overall rates of nosocomial infections, upper 
and lower respiratory tract infections, urinary tract infections, fungemias, central line 
27 
 
infection rates, wound infections, blood infections, other infections, nonprophylactic IV 
antibiotic use, length of stay (LOS) in the hospital, duration of intubation, need for 
reintubation, and in-hospital mortality. 
Study results pertinent to this review (Appendix E-3) demonstrated an overall 
decrease in all hospital-acquired infection rates in the CHG treated patients by 65% (P 
<0.01). Total respiratory tract infections were 69% less common in the CHG treated 
group (P<0.05) and the use of nonprophylactic IV antibiotics was lowered by 43% 
(P<0.05). Although they found no statistical differences between the two groups 
regarding average duration of mechanical ventilation, reintubation rate, or length of stay 
in the hospital, there was a reduction in mortality in the CHG group versus control group 
(1.16% vs. 5.56% respectively). 
Critical appraisal (Appendix D-3) of the DeRiso et al. (1996) study using CASP 
revealed it was unclear whether all patients that entered the study were accounted for at 
the end of the study. Researchers also did not state why they chose the sample size they 
selected; however, the sample that was selected did not statistically differ in 
characteristics. The trial did clearly address the focus issue and the randomized double-
blind placebo-controlled design gives the study further validity.  
Lin et al. (2015) investigated the effect of preoperative 0.2% CHG on 
postoperative VAP rates. Patients that met inclusion criteria were selected prior to cardiac 
surgery at a medical university hospital in China. Inclusion criteria were consciousness; 
age >18 years; ability to independently gargle in the oropharynx; and requiring 
orotracheal intubation and mechanical ventilation. The exclusion criteria were pneumonia 
before intubation; history of previous heart surgery and intubation; or severe brain, liver, 
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or kidney disease. Of the 94 patients that met the inclusion criteria, 47 were randomized 
to the CHG group and 47 to the control group. All patients were blinded to their 
grouping.  
The day prior to surgery the CHG group gargled with 50 mL 0.2% CHG 30 
minutes after all meals and 5 minutes after brushing teeth at bedtime. CHG was gargled 
for 30 seconds and was repeated three times at one-minute intervals while the control 
group gargled with normal saline adhering to the same schedule. Postoperatively, as part 
of standard care while on mechanical ventilation, both groups had oral rinses with 50 mL 
of 0.2% CHG, four times a day. After extubation, they were each required to gargle once 
with 50 mL of 0.2% CHG then once after each meal for three days. The oral care of all 
patients was performed by the same two trained healthcare professionals who were 
blinded to the patients grouping. The outcome of VAP was diagnosed using the 
simplified Clinical Pulmonary Infection Score (CPIS) and was assessed on days 1, 3, 5, 
and 7 after intubation with a threshold of ≥ 6.  Patients with CPIS ≥ 6 and < 6 were 
classified as those with and without VAP, respectively. 
Results of the study (Appendix E-4) revealed that preoperative CHG mouthwash 
reduced the incidence of postoperative VAP significantly; VAP occurred in 8.5% of the 
chlorhexidine group and 23.4% in the control group (P = 0.049). CPIS scores were not 
different between the two groups on postoperative day one; however, they were 
significantly lower in the CHG group on the third (P = 0.024) and fifth (P = 0.005) day 
when compared to the controls.  
Critical analysis of the Lin et al. (2015) study using the CASP checklist 
(Appendix D-4) revealed the study clearly addressed the focus of this review and met all 
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criteria other than the small sample size of only 47 in each group. To achieve a power of 
80% with a risk ratio of 0.36 over 90 patients would have been required in each group. 
The ideal power of 80% means the study would have a high chance of detecting a 
difference between the two groups. Since the study fell short of this goal without 
explanation, caution should be used when drawing conclusions as to whether there was a 
true difference between the two groups. The researchers had used a prior study to 
estimate the group sizing, which was 98 in each group, so they still fell short based on 
their initial needs assessment. This known small sample size is a limitation of the study. 
Additionally, the preoperative rinse was to be used the day before surgery after meals and 
before bed. This may lead to some patients receiving a different number of doses based 
on how many meals were eaten that day. The total mL of preoperative CHG and saline 
was not disclosed. Furthermore, self-reporting the correct use of four times a day 
preoperative CHG oral rinse may have led to error related to inaccurate reporting from 
patients.  The study design is unclear with researchers stating 1:1 randomization by 
computer generator followed by statements that the treating physician assigned the 
groups the day before surgery. Lastly, the study does not make clear if the two trained 
and blinded nurses performing oral care, data collection, and diagnosis of VAP were 








A cross study analysis table (Appendix E) was created to compare the RCTs used 
for this systematic review. The table includes which placebo was utilized, the CHG dose 
and frequency of administration and the effect on incidence of VAP.  
 A different placebo and CHG dose were used in each of the four RCTs. Munro et 
al. (2015) were the only researchers to investigate noncardiac surgery patients. They 
included patients from multiple clinical areas of the hospital including those prior to 
emergent intubations. The intervention group received 5 mL 0.12% CHG prior to 
intubation while the control group received no CHG prior to intubation. The intervention 
group received 5 mL 0.12% CHG by swab to the oral cavity administered by study 
personnel prior to intubation while the control group received none. After intubation both 
groups received 5 mL 0.12% CHG administered by the responsible nurse twice daily 
until extubation. Houston et al. (2002) used 15 mL of Listerine brand phenolic mouth 
rinse as the placebo. Each group received 15 mL of either the Listerine mixture or 0.12% 
CHG preoperatively (30 sec swish & spit) and twice daily postoperatively (30 sec swab) 
for 10 days postoperatively or until extubation, tracheostomy, death, or diagnosis of 
pneumonia. DeRiso et al. (1996) used a placebo with similar chemical makeup without 
CHG or antimicrobial properties that had identical packing. Either the placebo or the 
0.12% CHG was given twice daily preoperatively, however, the study failed to disclose 
for how many days. Postoperatively 15 mL of either solution as an oropharyngeal rinse or 
rigorously applied to the buccal, pharyngeal, gingival, tongue, and tooth surfaces for 30 
seconds twice daily until discharge from the ICU or death. Lastly, Lin et al., 2015 used 
0.9% saline solution as a placebo in the control group but did not specify the amount. The 
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day prior to surgery, patients gargled three times with 50 mL 0.2% CHG or the saline 
placebo 30 minutes after all meals and 5 minutes after brushing teeth at bedtime. Either 
solution was gargled for 30 seconds and was repeated three times at one-minute intervals. 
Once intubated both groups had oral rinse with 50 mL of 0.2% CHG four times a day.  
 Three of the four RCTs, Houston et al. (2002), DeRiso et al. (1996), and Lin et al. 
(2015), showed an improvement in VAP rates with the use of preintubation CHG. Only 
one RCT, the Munro et al. (2015) study, showed no benefit. There was no statistically 
significant improvement in the CPISs from the CHG group over the control group and 
both groups CPS scores remained less than the VAP threshold of 6. In regard to the 
study’s secondary aim of evaluating preintubations impact on ETT colonization, both 
groups were < 20% colonized with no significant difference (P = 0.8656).  
There were some variances in the amount of total risk reduction among the other 
three studies that found a reduction in VAP with the use of preintubation CHG. Houston 
et al. (2002) found the overall rate of nosocomial pneumonia was reduced by 52% (4/270 
vs 9/291; P =.21) in the CHG-treated patients. DeRiso et al. (1996) found VAP 69% less 
common in the CHG-treated group compared to the placebo group (5/173 vs 17/180; p < 
0.05). Lin et al. (2015) found an absolute risk reduction of VAP with the CHG group of 








The previously discussed differences in the dosages and application techniques 
may have influenced these varying results as well as many other factors that will be 
discussed in the summary and conclusions section.  
Ventilator-associated pneumonia is a major concern in hospitals that is correlated 
with increases in mortality, length of stay, and exponential increases in health care costs 
(Sedwick et al., 2012). In response to this, the IHI developed VAP bundles in 2006, which 
are evidenced-based interventions to improve patient outcomes. The inclusion of oral care 
with chlorhexidine 0.12% was made in the spring of 2010 after new clinical trials suggested 
an improvement in VAP rates. There have been multiple changes to the bundle over the 
years related to updated recommendations following new clinical trial. The ICS and NICE 
withdrew its recommendation for the use of oral chlorhexidine in non-cardiac surgery 
patients in 2016 after a new meta-analysis suggested its association with an increase in 
mortality (Hellyer et al., 2016). There is limited research exploring the proper time to 
initiate chlorhexidine. The purpose of this paper is to determine if the use of oral care with 
chlorhexidine prior to intubation impacts the incidence of ventilator-associated pneumonia.   
A comprehensive literature search for RCTs was performed using the databases 
CINHAL, Google Scholar, and Medscape. The PRISMA 27-item checklist and four-phase 
diagram (Moher et al., 2009) were utilized in the search process to ensure a thorough 
selection of studies. This search strategy resulted in four RCTs meeting inclusion criteria 
for this systematic review. Pertinent data from these studies were then organized into a data 
collection table (Appendices C1-4) allowing for comparison of the studies’ purposes, 
designs, sites and samples, methods, results, and limitations. The CASP checklist for RCTs 
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was used for critically appraisal to determine the scientific integrity of each of the four 
studies (Appendix D1-4). Lastly, a cross study analysis (Appendix E1-4) was performed 
to compare the placebo used in each study, the CHG dose selected, and the effects of the 
intervention variables on the incidence of VAP.   
Three of the four RCTs, Houston et al. (2002), DeRiso et al. (1996), and Lin et al., 
(2015), showed an improvement in VAP rates with the use of preintubation CHG. Only 
one RCT, the Munro et al., 2015 study, showed no benefit. This was the only study that 
included non-cardiac surgery patients. Researchers did not perform any analysis on the 
varying types of patients and the incidence on VAP. It is recommended that a secondary 
analysis be done specific to cardiac surgery patients to see the impact of CHG application 
on the incidence of VAP in this population. The Society of Thoracic Surgeons (STS) 
promotes the practice of extubating patients within 6 hours after cardiac surgery as a quality 
of care benchmark (Goeddel, Hollander & Evans, 2018) while other patient populations 
requiring mechanical ventilation tend to remain intubated longer. The inclusion of other 
patient populations in the Monroe et al. (2015) study may have negatively impacted results.  
One of the significant challenges in diagnosing VAP is that there is no recognized 
diagnostic gold standard or definition (Kollef, 2018) and the definition has evolved over 
time. VAP is currently a clinical diagnosis therefore subjective to some extent varying from 
provider to provider based on his or her interpretation. Fernando et al. (2020) found that 
none of the clinical diagnostic methods used to diagnose VAP were very accurate. Some 
of the radiographic, clinical, and laboratory indicators were combined into clinical 
diagnostic models, the most popular of which is the Clinical Pulmonary Infection Score 
(CPIS). This scale was also deemed unreliable by Fernando et al. (2020) with a sensitivity 
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of 73.8% (95% CI 50.6–88.5) and specificity of 66.4% (95% CI 43.9–83.3). There were 
differences in the four studies in the criteria used to diagnose VAP. The CPIS score was 
utilized in the Lin et al. (2015) and Munro et al. (2015) while the CDC criteria was used to 
diagnose VAP in the older RCTs DeRiso et al. (1996) and Houstan et. al (2002). Since 
none of the clinical diagnostic methods used to diagnose VAP were reliable perhaps more 
concrete primary outcomes such as mortality, duration of intubation, and antibiotic 
utilization should be used. 
Limitations  
There were several limitations in this systematic review. Only four studies met the 
inclusion and exclusion criteria which may affect generalizability. Also, all the RCTs were 
relatively small with each including between 94-561 participants. Practice differences 
related to ever changing standards of care plays a large factor in difficulties comparing the 
RCTs. Some of the trials date back prior to the initiation of the bundles; DeRiso et al. was 
published in 1996 and Houstan et. al in 2002, both well before the initiation of the IHI 
bundle in 2006. Therefore only Lin et al., (2015) and Munro et al., (2015) included all 
updates to the bundles to include elevation of the head of the bed to 30º to 45º; prophylaxis 
for peptic ulcer disease; prophylaxis for deep-vein thrombosis; daily interruption of 
sedation (sedation holiday); daily assessment of readiness for extubation; the use of 
subglottic secretion drainage ports for patients likely to require intubation > 48 hours and 
only changing the ventilator circuit as needed rather than on a fixed schedule as well as 
daily oral care with chlorhexidine. Therefore, the bundle itself is a cofounder in the newer 
studies since it may be responsible for some of the positive effects and CHG alone cannot 
be held solely accountable.  
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Another limitation with comparing studies is the differing concentrations of CHG 
used. A 0.12% concentration is currently the only oral formulation approved by the Food 
and Drug Administration (FDA) for use in the United States (Oral Care for Acutely and 
Critically Ill Patients, 2017). Lin et al. (2015) was the only study to use a strength other 
than 0.12%; researchers used 0.2% as the study was done in China where this concentration 
is available. All other studies were performed in the United States.  
Lastly, there is no worldwide standardized mouth care protocol. Each study had a 
different method, duration, length of time and process for the administration of either the 

















Summary and Conclusions 
The results of this systematic review demonstrate the use of CHG prior to intubation 
was effective in reducing the VAP rates in post-cardiac surgery patients in three of the four 
studies included in this review. These findings are not generalizable, however, related to 
the lack of large, randomized control trials including both cardiac and noncardiac patients. 
It remains unclear as to most effective dosing, frequency, and application procedure of 
CHG. The majority of patients in the studies were intubated for less than one week, 
however, some studies did not disclose an exact number of days. There is no evidence 
demonstrating a definitive time frame of CHG use related to length of intubation post 
cardiac surgery. Also, now that oral CHG is not being utilized in non-cardiac ICU patients, 
further studies of its use prior to intubation could be more accurate as they will not be 
receiving the CHG after intubation. More research is needed to determine effective dosing, 
frequency, and application procedures of CHG as well as exploring if it is safe to administer 
CHG prior to intubation in noncardiac surgery patients.  
Although there were several limitations in the RCTs and some differences made 
them difficult to compare, the achievement of the primary aim in this systematic review 
results in recommendations and implications that can be made for the advanced practice 







Recommendations and Implications for Advanced Nursing Practice 
The role of the advanced practice nurse (APN) has evolved to meet the challenge 
of access to health care across the United States. APNs have become an integral part of 
healthcare teams in both the inpatient and outpatient setting. APNs utilize evidence-based 
practice (EBP) methods to provide safe and efficient care to their patients. This 
systematic review presents evidence-based findings that may guide APNs in making 
informed decisions in future practice.  
Based on this systematic review, it can only be recommended that cardiac surgery 
patients receive CHG prior to and after intubation; however, more research needs to be 
done to determine the effective dosing, frequency, and application procedures as well as 
exploring if it is safe to administer CHG prior to intubation in noncardiac surgery 
patients.  
The results of this systematic review demonstrate the use of CHG prior to 
intubation was effective in reducing the VAP rates in three of the four studies included in 
this review; however, the three studies that did show an improvement only included 
cardiac surgery patients. Munro et al., (2015) was the only study to include non-cardiac 
surgery patients including emergent intubations and the results yielded no benefit with 
the use of CHG and VAP. The ICS and the NICE withdrew its recommendation for the 
use of oral CHG in non-cardiac surgery patients in 2016 after a new meta-analysis 
suggested its association with an increase in mortality (Hellyer et al., 2016). Now that 
oral CHG is not being utilized in non-cardiac ICU patients, further studies of its use prior 
to intubation could be more accurate as they will not be receiving the CHG after 
intubation.  APNs are in a position to lead research projects and develop new EBP 
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standards and implementation in clinical practice. In addition, they can develop safe 
policies and educate staff on safe practices.  
Further research is recommended. The next RCT trials to explore CHG prior to 
intubation should have larger sample sizes and the controls should be double blind.  
Utilizing different primary outcomes in these studies such as mortality, duration of 
intubation, and antibiotic usage may be more effective in quantifying VAP occurrences 
than the previously used ineffective CPIS scores. These outcomes may be more sensitive 
regarding the impact of VAP since there remains no gold standard for diagnosing it.  
The lack of a standardized approach to mouth care in the ICU setting was also 
evident throughout this review. The APN has the ability to work closely with 
interdisciplinary teams, including dentistry, to create one evidence-based, standard 
approach to oral care in intubated patients. Creating such a procedure with a stepwise 
approach would create continuity across ICUs worldwide.  
The current healthcare environment focus is on delivering superior patient care 
for less cost.  Low expenditure preventative interventions such as oral care with CHG 
could help reduce VAP rates and decrease mortality, length of stay, and costs. Ventilator-
associated pneumonia has a detrimental cost effect on the healthcare system and more 
research should be executed focused on prevention including trials of CHG application 
prior to intubation in noncardiac surgery patients. The APN can then use this knowledge 
to train bedside nurses who provide oral care to ensure it is performed appropriately. As 
research for VAP prevention advances, the diagnosis for this complex condition will be 
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Descriptive Data Tables 
Munro, C. L., Grap, M. J., Sessler, C. N., Elswick, R. K., Mangar, D., Karlnoski-Everall, R., & Cairns, P. (2015). Preintubation Application of Oral 
Chlorhexidine Does Not Provide Additional Benefit in Prevention of Early-Onset Ventilator-Associated Pneumonia. Chest, 147(2), 328–334. doi: 
10.1378/chest.14-0692 
Purpose Design Site/Sample Methods Results Limitations 
Primary aim to test the effect 
of preintubation 0.12% CHG 
in reducing VAP risk. 
Secondary aim to test the 
effect of preintubation 0.12% 





314 subjects from multiple clinical 
areas (just prior to intubation, 
including critical care units, EDs, 
preoperative areas, procedural areas, 
and medical surgical 
units during rapid response or code 
calls) were recruited by meeting 
inclusion criteria and being just prior 
to intubation at 2 large urban teaching 
hospitals in Virginia. Intervention 
group with CHG prior to intubation = 
157, control group = 157. 
 
IRB approved a waiver of prospective 
consent but required written 
documentation of consent (including 
information about voluntary 
withdrawal) from the subjects’ 
legally authorized representatives at 
the earliest opportunity following 
study enrollment. 
 
Mean age (SD): intervention group = 
59.5 (11.5), control group = 56.4 
(16.5) 
 
Gender: male/female in intervention 
group = 55/45, control group= 60/40 
 
Mean APACHE score (SD):  
intervention group = 81.2 (25.2) 
control group = 73.3  
(26.3) 
 
Exclusion criteria: Clinical diagnosis 
of pneumonia at time of intubation. 
 
Subjects randomly assigned to 
intervention group who received 
oral application of 5 mL CHG 
0.12% solution before intubation 
or to a control group who 
received no CHG before 
intubation.  
 
All subjects received CHG twice 
a day after intubation. 
 
Preop: oral application of 5 mL 
0.12% CHG solution by swab to 
the oral cavity administered by 
study personnel 
Postop: 5 mL 0.12% CHG 
administered by the responsible 
nurse on a twice daily schedule 
until extubation. 
 
Subjects remained in the study 
for a max of 6 days. If extubated 
prior to 6 days, the  
participation ended on the day of 
extubation.  
 
Groups were compared using a 
repeated-measures model with 
Clinical Pulmonary Infection 
Score (CPIS) as the response 
measure. ETTs were cultured at 
extubation. 
 
Clinical providers, laboratory 
personnel, and radiologists were 
all blinded to study groups.  
Application of a preintubation 
dose of CHG did not provide 
benefit.  
 
The P values from comparing 
each group’s change from 
baseline with study days 2, 3, 
4, and 5 were 0.4217, 0.9930, 
0.1484, and 0.1763, 
respectively.  
 
ETT colonization at 
extubation was 20% in both 
groups; no statistically 
significant difference (P = 
0.8656).  
 
Mean CPIS remained below 6 
(VAP threshold score) in both 
groups. 
Relatively small sample size 
but priori power analysis 
utilized to determine sample 
size required. 
 
May have been variations in 
the procedure of swabbing the 
oral cavities postintubation 
since this was done by staff at 
the hospital not the study 
personnel.  
 
Most subjects were extubated 
prior to the full 5-day 
intervention period. 
 
No standard noted for the 
procedure of swabbing to 
ensure continuity. 
  
Medical records were audited 
to ensure postintubation 
administration of CHG was 
given so there may be a 
chance it was scanned but not 
given. 
 
Does not state how 
randomization was achieved 
or what inclusion criteria was 
besides being prior to 
intubation without an existing 








Houston, S., Hougland, P., Anderson, J. J., LaRocco, M., Kennedy, V., & Gentry, L. O. (2002). Effectiveness of 0.12% chlorhexidine gluconate oral rinse in 
reducing prevalence of nosocomial pneumonia in patients undergoing heart surgery. American journal of critical care: an official publication, American 
Association of Critical-Care Nurses, 11(6), 567–570. 
Purpose Design Site/Sample Methods Results Limitations 
To test the effectiveness of 
0.12% CHG oral rinse in 
decreasing microbial 
colonization of the respiratory 
tract and nosocomial 
pneumonia in patients 






St. Luke’s Episcopal Hospital 
in Houston, Tx; a tertiary care 
center. 
 
All eligible patients who 
underwent aortocoronary 
bypass graft and/or valve 
surgery requiring 
cardiopulmonary bypass were 
invited to participate.  
 
 
Exclusion criteria: death 
during surgery, pregnant, or 
had a preoperative respiratory 
infection that had been 
documented in the medical 
record or reported by the 
patient. 
 
561 patients included in the 
final data analysis, 270 were 
randomized to the CHG 
(experimental) group and 291 
to the Listerine (control) 
group. 
 
Gender: male in intervention 
group = 73%, control group = 
79% 
Randomized by medical record 
numbers.  
Intervention group was 0.12% CHG, 
Listerine brand phenolic mouth rinse 
was the standard agent for routine oral 
care (control group). 
Participants received 15 mL of either  
CHG or Listerine oral rinse 
preoperatively (30 sec swish & spit) 
and twice daily postoperatively (30 
sec swab) for 10 days postoperatively 
or until extubation, tracheostomy, 
death, or diagnosis of pneumonia. 
Oral rinses dispensed by pharmacists 
and administered by nurses. 
Both groups received perioperative 
prophylactic antibiotics per cardiac 
surgery protocol. 
Sputum samples were collected at the 
time of extubation. For intubation > 
24 hours of surgery, sputum samples 
were obtained routinely every 48 
hours until extubation. 
Infections were diagnosed by using a 
tool based on the CDC criteria for 
nosocomial pneumonia  
 
Rates of nosocomial 
pneumonia were lower in 
patients treated with CHG 
than in patients treated with 
Listerine, but the difference 
was significant only in those 
patients intubated >24 hours 
who had the highest degree of 
bacterial colonization. 
The overall rate of 
nosocomial pneumonia was 
reduced by 52% (4/270 vs. 
9/291; P =.21) in the CHG-
treated patients.  
Among patients intubated for 
> 24 hours who had cultures 
that showed microbial growth 
(all pneumonias occurred in 
this group); the pneumonia 
rate was reduced by 58% 
(4/19 vs. 9/18; P = .06) in 
patients treated with CHG.  
In patients at highest risk for 
pneumonia (intubated >24 
hours, with cultures showing 
the most growth), the rate was 
71% lower in the CHG group 
than in the Listerine group 
(2/10 vs. 7/10; P =.02). 
Because of the low 
overall pneumonia rate, a 
large sample size would be 
required to detect a 
significant difference in 
infection rate between the 
CHG and the Listerine  
groups.  
 
There was no blinding in this 
study.  
 
Does not include age ranges 
of participants. 
 
Does not state how many 
doses of oral rinse patients 
received in total 
preoperatively.  
 
There could be error in self-
reporting of the preoperative 
doses that patients did at 
home. Some doses may have 







DeRiso, A. J., 2nd, Ladowski, J. S., Dillon, T. A., Justice, J. W., & Peterson, A. C. (1996). Chlorhexidine gluconate 0.12% oral rinse reduces the incidence of 
total nosocomial respiratory infection and nonprophylactic systemic antibiotic use in patients undergoing heart surgery. Chest, 109(6), 1556–1561. 
https://doi.org/10.1378/chest.109.6.1556 
Purpose Design Site/Sample Methods Results Limitations 
Primary aim was to test the 
hypothesis that the 
preoperative use of twice-
daily 0.12% CHG oral rinse 
can reduce nosocomial 
infection rates in patients 
undergoing open heart 
surgery. 
Additional outcome measures 
• Overall nosocomial 
infection rates 
• Upper and lower 
respiratory tract infection 
rates 
• Urinary tract infection rates 
• Fungemias 
• Line infection rates 
• Wound infection rates 
• Blood infection rates 
• Other infections 
• Nonprophylactic IV 
antibiotic use 
• Length of stay (LOS) in the 
hospital 
• Duration of intubation 
• Need for reintubation 
• In-hospital mortality 
Prospective, randomized, 
double-blind, placebo-
controlled clinical trial 
Cardiovascular ICU at 
Lutheran Hospital of Indiana, 
a tertiary care hospital 
353 consecutive patients 
undergoing coronary artery 
bypass grafting, valve, or 
other open-heart surgical 




preoperative infection or 
intubation, pregnancy, heart 
and lung transplant recipients, 
and known hypersensitivity to 
CHG. 
Consecutive eligible patients 
over a 10-month period prior 
to cardiac surgery were 
invited to participate.  
Gender: male/female in 
intervention group = 119/54, 
control group = 123/57 
Mean ages intervention group 
= 64.1, control group = 63.5. 
 
Participants were randomized 
by computer-driven random 
number generator into either 
the CHG 0.12% or placebo 
solutions that were liquids of 
comparable color, taste, and 
smell were dispensed. Oral 
rinse given preoperatively and 
twice daily postoperatively 
until discharge from the ICU 
or death. 
Doses were 0.5 fl oz (15 mL) 
as an oropharyngeal rinse or 
rigorously applied to the 
buccal, pharyngeal, gingival, 
tongue, and tooth surfaces for 
30 seconds twice daily. 
Both groups received 
perioperative prophylactic 
antibiotics per cardiac surgery 
protocol. 
Patients who failed early 
extubation (within 24 hours) 
received tracheal aspirate 
culture analysis at 48 hours 
and then every 2 days until 
discharged from the ICU or 
death. Infections were 
diagnosed by CDC criteria for 
nosocomial pneumonia. 
The overall nosocomial 
infection rate was decreased 
in the CHG-treated 
patients compared to the 
placebo group by 65% (8/173 
vs. 24/180; p < 0.0l) 
respectively. 
 
Respiratory tract infections 
were 69% less common in the 
CHG-treated group compared 
to the placebo group (5/ 
173 vs. 17/180; p < 0.05). 
A reduction in mortality in 
the CHG-treated group was 
also noted (1.16% vs. 5.56%). 
Does not specify how long 
preoperatively patients used 
CHG.  
 
There could be error in self-
reporting of the preoperative 
doses that patients did at 
home. Some doses may have 







Lin, Y. J., Xu, L., Huang, X. Z., Jiang, F., Li, S. L., Lin, F., Ye, Q. Y., Chen, M. L., & Lin, J. L. (2015). Reduced occurrence of ventilator-associated 
pneumonia after cardiac surgery using preoperative 0.2% chlorhexidine oral rinse: results from a single-centre single-blinded randomized trial. The Journal of 
hospital infection, 91(4), 362–366. https://doi.org/10.1016/j.jhin.2015.08.018 
Purpose Design Site/Sample Methods Results Limitations 
To investigate the effect of 
preoperative 0.2% CHG on 





Patients who met inclusion 
and exclusion criteria from 
those scheduled for cardiac 
surgery between August 
2013 and April 2014 at the 
Fujian Medical University 
Union Hospital, China. 
The inclusion criteria were 
conscious; age >18 years; 
able to gargle in the 
oropharynx by themselves; 
and required orotracheal 
intubation and mechanical 
ventilation.  
The exclusion criteria were 
pneumonia before 
intubation; history of 
previous heart surgery and 
intubation; or severe brain, 
liver, or kidney disease. 
Of the 94 patients who met 
the inclusion criteria, 47 
were randomized to the 
CHG group and 47 to the 
control group. 
 
1:1 Randomization was by a 
computer-generated random 
number table and sealed 
envelopes prepared by a 
statistician. The treating 
physician assigned the patient to 
a group the day before surgery. 
All patients were blinded to their 
grouping.  
In the CHG group, patients 
gargled with 50 mL 0.2% CHG 
30 minutes after all meals and 5 
minutes after brushing teeth at 
bedtime. CHG was gargled for 
30 seconds and was repeated 
three times at one-minute 
intervals while the control group 
gargled with normal saline 
adhering to the same schedule. 
All oral care and data collection 
were done by same two trained 
and blinded nurses to avoid bias.  
The outcome of VAP was 
diagnosed using the simplified 
Clinical Pulmonary Infection 
Score (CPIS) and was assessed 
on days 1, 3, 5, 
and 7 after intubation.  A CPIS 
score > 6 is suggestive of 
pneumonia.    
VAP occurred in 4 patients (8.5%) in 
the CHG group and in 11 patients 
(23.4%) in the control group (P=0.049).  
VAP within 5 days was defined as early 
onset and VAP after five days was late 
onset. 
In the CHG group, there was 1 case of 
early onset VAP (25.0%) and 3 cases of 
late onset VAP (75.0), whereas in the 
control group, there were 9 cases of 
early onset VAP (81.8%) and 2 cases of 
late onset VAP (18.2%) (P = 0.027).  
The relative risk for VAP in the CHG 
group was 0.36 8.5% versus 23.4% in 
the control group 
 The absolute risk reduction was 14.9% 
in the CHG group and (23.4%/8.5%). 
The number needed to treat was 6.7 
(1/0.149). 
CPIS scores were not different between 
the two groups on postoperative day 1; 
however, they were significantly lower 
in the CHG group on the 3rd (P = 
0.024) and 5th (P = 0.005) days when 
compared to the controls.  
Since only 2 and 3 cases completed 
data collection on the 7th day in the 
CHG and control groups, respectively, 
because they were extubated no 
analysis could be performed. 
The preoperative rinse was used 
the day before surgery after 
meals and before bed; some 
patients may have used different 
amounts of doses based on how 
many meals eaten that day. 
Total mL of preoperative CHG 
and saline was not disclosed. 
Risk for self-reporting error by 
patients about how often they 
performed the preoperative rinse  
The sample size was small and 
to achieve a power of 80% at a 
risk ratio of 0.36 over 90 
patients would have been 
required in each arm. 
The presence of VAP was only 
analyzed for the first seven 
postoperative days. 
 
Unclear study design stating 1:1 
randomization by computer 
generator but then states 
physician assigned the groups.  
 
Study does not make clear if the 
two trained and blinded nurses 
performing oral care, data 
collection, and diagnosis of 
VAP were from their team or 






Munro, C. L., Grap, M. J., Sessler, C. N., Elswick, R. K., Mangar, D., Karlnoski-Everall, R., & 
Cairns, P. (2015). Preintubation Application of Oral Chlorhexidine Does Not Provide Additional 
Benefit in Prevention of Early-Onset Ventilator-Associated Pneumonia. Chest, 147(2), 328–334. 
doi: 10.1378/chest.14-0692 
1 Did the trial address a clearly focused issue? Yes   Can’t 
tell 
No 
2 Was the assignment of patients to treatments randomized? Yes Can’t 
tell 
No 










5 Were the groups similar at the start of the trial? Yes  Can’t 
tell 
No 





7 How large was the treatment effect? ETT colonization at extubation 
was, 20% in both groups (no statistically significant difference P 
=0.8656).  
Yes  Can’t 
tell 
No 
8 How precise was the estimate of the treatment effect? A logistic 
regression analysis was performed using the binary response 
variable of colonization or no colonization and dependent variables 
for group, length of intubation, and group-by-length-of-intubation 
interaction. The probability of a type 1 error (alpha) was set to 0.05. 
Yes  Can’t 
tell 
No 





10 Were all clinically important outcomes considered? Yes Can’t 
tell 
No 






Houston, S., Hougland, P., Anderson, J. J., LaRocco, M., Kennedy, V., & Gentry, L. O. (2002). 
Effectiveness of 0.12% chlorhexidine gluconate oral rinse in reducing prevalence of nosocomial 
pneumonia in patients undergoing heart surgery. American journal of critical care: an official 
publication, American Association of Critical-Care Nurses, 11(6), 567–570. 
1 Did the trial address a clearly focused issue? Yes   Can’t 
tell 
No 
2 Was the assignment of patients to treatments randomized? Yes Can’t 
tell 
No 
3 Were all the patients who entered the trial properly accounted for at 









5 Were the groups similar at the start of the trial? Yes  Can’t 
tell 
No 





7 How large was the treatment effect? The overall rate of nosocomial 
pneumonia was reduced by 52% (4/270 vs. 9/291; P=.21) in the 
CHX patients. 
Yes  Can’t 
tell 
No 
8 How precise was the estimate of the treatment effect? This sample 
size was sufficient to detect a 0.20 effect size with 99% power.  
Yes  Can’t 
tell 
No 





10 Were all clinically important outcomes considered? Yes Can’t 
tell 
No 








DeRiso, A. J., 2nd, Ladowski, J. S., Dillon, T. A., Justice, J. W., & Peterson, A. C. (1996). 
Chlorhexidine gluconate 0.12% oral rinse reduces the incidence of total nosocomial respiratory 
infection and nonprophylactic systemic antibiotic use in patients undergoing heart surgery. Chest, 
109(6), 1556–1561. https://doi.org/0.1378/chest.109.6.1556 
1 Did the trial address a clearly focused issue? Yes   Can’t 
tell 
No 
2 Was the assignment of patients to treatments randomized? Yes Can’t 
tell 
No 










5 Were the groups similar at the start of the trial? Yes  Can’t 
tell 
No 





7 How large was the treatment effect? 69% reduction in the incidence 
of total respiratory tract infections in the CHX-treated group (17/180 
vs. 5/173; p<0.05). A reduction in mortality in the CHX-treated 
group was also noted (1.16% vs. 5.56%). 
Yes  Can’t 
tell 
No 
8 How precise was the estimate of the treatment effect? Statistical 
analysis was carried out via computer using software (Systat 
Statistical). Analysis of variance was used to compare numeric data, 
while the x2 test with Yates' correction or the Fisher's Exact Test 
was used for categorical data depending on the sample size. In all 
cases, significance was defined as p<0.05. 
Yes  Can’t 
tell 
No 





10 Were all clinically important outcomes considered? Yes Can’t 
tell 
No 







Lin, Y. J., Xu, L., Huang, X. Z., Jiang, F., Li, S. L., Lin, F., Ye, Q. Y., Chen, M. L., & Lin, J. L. 
(2015). Reduced occurrence of ventilator-associated pneumonia after cardiac surgery using 
preoperative 0.2% chlorhexidine oral rinse: results from a single-centre single-blinded randomized 
trial. The Journal of hospital infection, 91(4), 362–366. https://doi.org/10.1016/j.jhin.2015.08.018 
 
1 Did the trial address a clearly focused issue? Yes   Can’t 
tell 
No 
2 Was the assignment of patients to treatments randomized? Yes Can’t 
tell 
No 










5 Were the groups similar at the start of the trial? Yes  Can’t 
tell 
No 





7 How large was the treatment effect? VAP occurred in four patients 
(8.5%) in the chlorhexidine group and in 11 patients (23.4%) in the 
control group (P ¼ 0.049).  
Yes  Can’t 
tell 
No 
8 How precise was the estimate of the treatment effect? Based on a 
previous study, the estimated incidence of VAP was 30% in the 
placebo group and 15% in the study group, resulting in an estimated 
sample size of 98 patients in each arm, for a power of 80% and alpha 
=0.05.  
Yes  Can’t 
tell 
No 





10 Were all clinically important outcomes considered? Yes Can’t 
tell 
No 












Effect on Incidence of 
VAP (Results) 








Preintubation: 5 mL 
0.12% CHG by swab 
to the oral cavity 
administered by study 
personnel 
Postop: 5 mL 0.12% 
CHG administered by 
the responsible nurse 
twice daily until 
extubation 
Application of a 
preintubation dose of 
CHG did not provide 
benefit in reducing 
incidence of VAP 
 
Mean CPIS < 6 (VAP 
threshold score) in both 
groups. 
 
Secondary aim of 
evaluating preintubations 
impact on ETT 
colonization: both groups 
were < 20% colonized 
with no significant 
difference (P = 0.8656). 
 
Houston et al., 2002 
 
 




(Given on same 
schedule as CHG 
administration) 
15 mL 0.12% 
preoperatively (30 
second swish & spit) 
and twice daily 
postoperatively (30 
second swab) for 10 
days postoperatively 
or until extubation, 
tracheostomy, death, 
or diagnosis of 
pneumonia. 
The overall rate of 
nosocomial pneumonia 
was reduced by 52% 
(4/270 vs. 9/291; P = .21) 
in the CHG-treated 
patients.  
Among patients intubated 
for > 24 hours who had 
cultures that showed 
microbial growth (all 
pneumonias occurred in 
this group); the 
pneumonia rate was 
reduced by 58% (4/19 vs. 
9/18; P = .06) in patients 
treated with CHG.  
In patients at highest risk 
for pneumonia (intubated 
>24 hours, with cultures 
showing the most 
growth), the rate was 71% 
lower in the CHG group 
than in the Listerine group 









Effect on Incidence of 
VAP (Results) 












(Given on same 




CHG (unspecified for 
how many days 
preoperatively). Then 
postoperatively 15 
mL 0.12% as an 
oropharyngeal rinse 
or rigorously applied 
to the buccal, 
pharyngeal, gingival, 
tongue, and tooth 
surfaces for 30 
seconds twice daily 
until discharge from 




were 69% less common in 
the CHG-treated group 
compared to the placebo 
group (5/173 vs. 17/180; 
p < 0.05). 








(Given on same 
schedule as CHG 
administration)  
50 mL 0.2% CHG 30 
minutes after all 
meals and 5 minutes 
after brushing teeth at 
bedtime. Either 
solution was gargled 
for 30 seconds and 
was repeated three 
times at one-minute 
intervals. Once 
intubated both groups 
had oral rinse with 50 
mL of 0.2% CHG 
four times a day. 
 
VAP occurred in 4 
patients (8.5%) in the 
CHG group and in 11 
patients (23.4%) in the 
control group (P = 0.049).  
 
Absolute risk reduction 
was 14.9% (23.4%/8.5%). 
 
